ABX 464 Aims to Reduce HIV Reservoirs

Revving Up Investigational agent ABX 464 seeks to reduce HIV reservoirs by Jeannie Wraight ABX 464 is making its way through clinical trials, showing strong potential as...

Expediting Research

GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...

David Evans

Risk & Reward Activist David Evans weighs in on next steps in cure advocacy & research by Jeannie Wraight In the late 1980s and throughout the ’90s,...

Cure Research: CROI 2018

Fast Look Cure research highlights from CROI 2018 by Jeannie Wraight The Conference on Retroviruses and Opportunistic Infections (CROI) provides an annual snapshot of the year’s most...

Post-Treatment Controllers & HIV Treatment

Control Issues What can post-treatment controllers tell us about HIV care and treatment? by Jeannie Wraight In order to keep their virus suppressed, most people living with...

JAK Inhibitors

JAK of All Trades Researchers look to JAK inhibitors as part of hiv treatment & eradication by Jeannie Wraight R research on three Janus kinase inhibitors (JAK...

amfAR’s “Next Generation” of Cure Research

Planting Seeds amfAR Rolls Out Its “Next Generation” of Funded HIV Cure Research by Chip Alfred On December 3, 2020 in honor of World AIDS Day, amfAR...

The New Administration & the Threat to HIV Care and Cure...

Buyer Beware The new administration may threaten HIV care and cure research by Jeannie Wraight Our way of life in the U.S. has already drastically changed as...

LATEST POSTS

Ron B: Cover Story

“You had me at Angels in America,” I tell Ron B. when I see her at the Manhattan Neighborhood Network studios, in New York...